Drug Profile

BHV 1300

Alternative Names: BHV-1300

Latest Information Update: 11 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biohaven Pharmaceuticals
Class Antirheumatics
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Rheumatoid arthritis
Preclinical Immunological disorders

Most Recent Events

28 May 2025 Updated efficacy data from a phase I trial in Rheumatoid arthritis released by Biohaven
28 May 2025 Biohaven plans a phase-II trial for Graves disease in the second half of 2025 (SC)
16 Dec 2024 Updated efficacy and adverse events data from a phase I trial in Rheumatoid arthritis released by Biohaven

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com